RESUMO
For oral drug products, in vitro dissolution is the most used surrogate of in vivo dissolution and absorption. In the context of drug product quality, safe space is defined as the boundaries of in vitro dissolution, and relevant quality attributes, within which drug product variants are expected to be bioequivalent to each other. It would be highly desirable if the safe space could be established via a direct link between available in vitro data and in vivo pharmacokinetics. In response to the challenges with establishing in vitro-in vivo correlations (IVIVC) with traditional modeling approaches, physiologically based biopharmaceutics modeling (PBBM) has been gaining increased attention. In this manuscript we report five case studies on using PBBM to establish a safe space for BCS Class 2 and 4 across different companies, including applications in an industrial setting for both internal decision making or regulatory applications. The case studies provide an opportunity to reflect on practical vs. ideal datasets for safe space development, the methodologies for incorporating dissolution data in the model and the criteria used for model validation and application. PBBM and safe space, still represent an evolving field and more examples are needed to drive development of best practices.
Assuntos
Biofarmácia , Modelos Biológicos , Administração Oral , Biofarmácia/métodos , Formas de Dosagem , Liberação Controlada de Fármacos , Solubilidade , Equivalência TerapêuticaRESUMO
BACKGROUND: Of the various drug therapies that influence gastrointestinal (GI) physiology, one of the most important are the acid-reducing agents (ARAs). Because changes in GI physiology often influence the pharmacokinetics of drugs given orally, there is a need to identify in vitro methods with which such effects can be elucidated. OBJECTIVE: Literature concerning the effects of ARAs (antacids, H2-receptor antagonists, and proton pump inhibitors [PPIs]) on GI physiology are reviewed with the aim of identifying conditions under which drugs are released after oral administration in the fasted state. In vitro dissolution tests to mimic the effects in the stomach were designed for H2-receptor antagonists and PPIs. CONCLUSIONS: The impact of ARAs on GI physiology depends on the type, duration, and amount of ARA administered as well as the location in the GI tract, with greatest impact on gastric physiology. While ARAs have a high impact on the gastric fluid pH and composition, changes in volume, viscosity, surface tension, and gastric emptying appear to be less profound. The proposed dissolution tests enable a ready comparison between dosage form performance in healthy adults and those receiving PPIs or H2-receptor antagonists.
Assuntos
Antiácidos/farmacologia , Antiácidos/uso terapêutico , Trato Gastrointestinal/efeitos dos fármacos , Trato Gastrointestinal/fisiologia , Administração Oral , Animais , Esvaziamento Gástrico/efeitos dos fármacos , Esvaziamento Gástrico/fisiologia , Humanos , Solubilidade/efeitos dos fármacosRESUMO
In this article, experiments on tablets containing a model compound, grazoprevir, were conducted to explore how media selection for a quality control dissolution method can influence the sensitivity for the dissolution method toward drug crystallinity detection in an amorphous solid dispersion formulation. The experiment shows that under ideal nonsink conditions with respect to crystalline solubility, dissolution can indeed be predictive of crystallinity in the formulation. However, the limit of detection for crystallinity with quality control dissolution can change based on inherent variabilities in the drug product. In addition, it is demonstrated that the method's sensitivity and accuracy might be reduced if the crystalline particles are sufficiently small with respect to the solid dispersion particles. To further demonstrate the limits of the dissolution method, a dissolution model was also explored to simulate and predict the sensitivity of the dissolution response toward crystallinity based on solubility in the media and particle size of the crystals.
Assuntos
Química Farmacêutica/métodos , Composição de Medicamentos/normas , Modelos Químicos , Controle de Qualidade , Quinoxalinas/farmacocinética , Amidas , Carbamatos , Cristalização , Ciclopropanos , Liberação Controlada de Fármacos , Estudos de Viabilidade , Limite de Detecção , Tamanho da Partícula , Quinoxalinas/química , Solubilidade , Sulfonamidas , ComprimidosRESUMO
A slowdown in dissolution performance has been observed for an immediate release tablet formulation during long-term stability testing. The slowdown was successfully predicted using an accelerated stability study in which the dissolution was tested over a range of temperatures, humidity conditions and storage times. The slowdown was quantified using a calculated parameter referred to as the "acceleration factor" (AF); this is the degree by which the timescale (x-axis) of a dissolution profile needs to be scaled to overlay it on to the dissolution profile obtained at the initial timepoint. The "AF" approach was applicable because it was observed that the shape of the dissolution profile remains consistent even though different dissolution rates were obtained. Under the accelerated stability conditions, the AF is observed to follow an "exponential decay" curve. A predictive model for the long-term stability dissolution was obtained by modeling both the plateau level and the rate constant for the exponential decay curve as functions of temperature and humidity. The long-term stability of product A in packaging was successfully predicted using this model in combination with simulations of the changing relative humidity conditions inside the packaging.
Assuntos
Solubilidade/efeitos dos fármacos , Comprimidos/química , Embalagem de Medicamentos/métodos , Estabilidade de Medicamentos , Umidade , TemperaturaRESUMO
Solution proton nuclear magnetic resonance analysis was used in conjunction with in vitro lipolysis to elucidate the time-dependent speciation and release of lipolytic products during the digestion of lipid-loaded inorganic particles, allowing correlations to be made between the phase partitioning of lipolytic products and an encapsulated poorly soluble drug. Silicon dioxide, montmorillonite, and laponite were used to encapsulate medium chain triglycerides into solid-state lipid-based formulations (LBFs), and coumarin 102 was selected as a model poorly soluble compound. The specific inorganic carrier material used to encapsulate medium chain triglycerides significantly impacted the release and partitioning of the solubilizing lipolytic products, that is, diglycerides, monoglycerides, and fatty acids. A strong linear correlation was obtained between drug solubilization and fatty acid release to the aqueous phase (R2 = 0.996), indicating fatty acids to be the most important lipid species for enabling solubilization and potential drug absorption in vivo. This method was developed to improve upon the use of pH-stat titration for characterizing LBF digestion during in vitro lipolysis studies and is demonstrated herein to provide useful insights into how the selected inorganic carrier material impacts LBF performance when solid-state LBF powders are fabricated via adsorption.
Assuntos
Portadores de Fármacos/química , Composição de Medicamentos , Lipídeos/química , Lipólise , Modelos Biológicos , Preparações Farmacêuticas/química , Bentonita/química , Digestão , Humanos , Espectroscopia de Prótons por Ressonância Magnética , Silicatos/química , Dióxido de Silício/química , SolubilidadeRESUMO
Solubility, dissolution, and precipitation in the gastrointestinal tract can be critical for the oral bioavailability of weakly basic drugs. To understand the dissolution and precipitation during the transfer out of the stomach into the intestine, a multicompartment transfer system was developed by modifying a conventional dissolution system. This transfer system included gastric, intestinal, sink and supersaturation, and reservoir compartments. Simulated gastric fluid and fasted state simulated intestinal fluid were used in the gastric and intestinal compartment, respectively, to mimic fasted condition. The new transfer system was evaluated based on 2 model weak bases, dipyridamole and ketoconazole. Traditional 2-stage dissolution using 250 mL of simulated gastric fluid media, followed by 250 mL of fasted state simulated intestinal fluid, was used as a reference methodology to compare dissolution and precipitation results. An in silico model was built using R software suite to simulate the in vitro time-dependent dissolution and precipitation process when formulations were tested using the transfer system. The precipitation rate estimated from the in vitro data was then used as the input for absorption and pharmacokinetic predictions using GastroPlus. The resultant simulated plasma concentration profiles were generally in good agreement with the observed clinical data, supporting the translatability of the transfer system in vitro precipitation kinetics to in vivo.